Team CHEVRET
Clinical Epidemiology and Statistics for Therapeutic Trials and Observational Data (ECSTRRA)Learn more about the team
Our team uniquely combines statisticians and clinician-researchers specialized in hematology and immunology. All conduct internationally recognized research, as evidenced by the quality of the team’s publications. Our biostatistical research could be described as “translational” between statistical models and the application of their results to patients. Our team is also heavily involved in the planning and management of clinical trials promoted by AP-HP or other bodies, and in the constitution and monitoring of cohorts or clinical trials, for example in adult acute leukemias (ALFA, GRAALL, THEMA) or childhood acute leukemias (CAALL), and immune deficiencies (DEFI).
Our research project is centered on improving responses to clinical and biological questions concerning patients with severe diseases requiring intensive or prolonged hospitalization and treatments. Our multidisciplinary team proposes biostatistical, clinical epidemiology, and public health approaches for clinical research conducted by team members or by the future center. The biostatistical axes of our research are (i) innovative designs for adaptive clinical trials, (ii) detailed modeling of cohort and real-world data, and (iii) integration of external data in evaluation.
Axes explorés
Axis 1 – Bayesian inference
Our objectives are to propose innovative methods for conducting clinical trials by suggesting approaches that better incorporate current knowledge on the efficacy or toxicity of a new drug. For example, we evaluate innovative adaptive designs that allow the integration of multiple dimensions (using tolerance and efficacy outcomes, from the physician and the patient level) for the selection of an optimal dose level of advanced therapy medicinal products (ATMP).
Axis 2 – Causal inference
We develop valid causal inference approaches for the incorporation of non-interventional study data (either available at the individual patient level or only aggregated summary data) in the analysis of interventional trial data (such as single-arm-trial), accounting for the specificities of hematology data — notably the relatively small sample sizes, often imbalanced treatment groups, and the right-censored nature of endpoints.
Axis 3 – Prognostic and predictive models
Our objectives are to provide measures for evaluating the prognostic value of a new classification or prognostic markers, to study different strategies for the joint modeling of longitudinal and survival data (in the broad sense), particularly within the framework of multi-state models, with a special focus on assessing the surrogacy of intermediate outcome measures.
Team members
Cécile PERRIER
Clinical psychologist
Déborah AZOULAY
Hospital Secretary/Administrative Manager
Team alumni
Arnaud SERRET-LARMANDE
Arnaud TARANTOLA
Aurélien LATOUCHE
Claire MONTLAHUC
Corinne ALBERTI
Emmanuel CARUANA
Emmanuelle DESLANDES
Guillaume DUMAS
Jacques-Emmanuel GALIMARD
Jean-François TIMSIT
Karl CHAMPEAUX
Leslie PIBOULEAU
Lilith FAUCHEUX
Luana BOUMENDIL
Ményssa CHERIFA
Olivier PEYRONY
Sandrine KATSAHIAN
Sarah ZOHAR
Tai Olivier PHAM
Publications
2026 Emerg Infect Dis.
Multicenter Retrospective Study of Invasive Fusariosis in Intensive Care Units, France
Jordane Demonchy, Lucie Biard, Raphaël Clere-Jehl, Florent Wallet, Djamel Mokart, Anne-Sophie Moreau, Laurent Argaud, Camille Verlhac, Frédéric Pène, Alexandre Lautrette, Naïke Bige, Audrey de Jong, Emmanuel Canet, Jean-Pierre Quenot, Nahéma Issa, Yoann Zerbib, Inès Bouard, Muriel Picard, Lara Zafrani
View2026 Blood Adv.
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study
Sarah Cayla, Lionel Karlin, Jérôme Lambert, Anne Lazareth, Alexis Talbot, Mohamad Mohty, Florent Malard, Marie-Odile Petillon, Salomon Manier, Ibrahim Yakoub-Agha, Denis Caillot, Ingrid Lafon, Xavier Leleu, Niels Moya, Bruno Royer, Jean-Marc Schiano De Colella, Gabriel Brisou, Cyrille Touzeau, Aurore Perrot, Pierre Bories , Laure Vincent, Hanane Guedon, Olivier Decaux, Benoît Ferment, Roch Houot, Steven Le Gouill, Noémie Bigot, Thierry Facon, Jill Corre, Hervé Avet-Loiseau, Philippe Moreau, Bertrand Arnulf
View2026 Blood
Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.
Nicolas Boissel, Sylvie Chevret, Françoise Huguet, Thibaut Leguay, Mathilde Hunault, Carlos Graux, Yves Chalandon, Eric Delabesse, Yosr Hicheri, Patrice Chevallier, Marie Balsat, Cédric Pastoret, Martine Escoffre-Barbe, Florence Pasquier, Magalie Joris, Anne Thiebaut, Anne Huynh, Nathalie Dhédin, Emilie Lemasle, Caroline Bonmati, Sébastien Maury, Gaëlle Guillerm, Ana Berceanu, Markus Manz, Thomas Cluzeau, Pascal Turlure, Philippe Rousselot, Bernard de Prijck, Nathalie Grardel, Marie C. Béné, Marina Lafage-Pochitaloff, Wendy Cuccuini, Norbert Ifrah, Véronique Lhéritier, Vahid Asnafi, Emmanuelle Clappier, Hervé Dombret
View2026 Blood Adv
Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availability
Marie Sébert, Sylvain Thepot, Thomas Cluzeau, Nicolas Duployez, Thibaud Lefèbvre, Cendrine Chaffaut, Corentin Orvain, Michael Loschi, Pierre Peterlin, Patrice Chevallier, Maud D'Aveni, Marie Thérèse Rubio, Odile Rauzy, Anne Huynh, Amandine Charbonnier, Rosa Sapena, Fatiha Chermat, Patrice Ceballos, Gaelle Fossard, Stéphanie Nguyen, Sophie Park, Lionel Adès, Régis Peffault de Latour, Claude Preudhomme, Pierre Fenaux, Sylvie Chevret, Marie Robin
View
